原发与挽救性背景下高强度聚焦超声部分腺体治疗前列腺癌的系统综述
该系统综述检索MEDLINE与Embase至2016年10月10日,纳入13项研究共543例患者,其中11项为原发治疗、2项为挽救治疗,中位随访6个月至10.6年。治疗后勃起功能障碍发生率0%至48%、尿失禁0%至50%,共报告254例并发症,76例(14%)后续接受进一步肿瘤治疗。作者认为早期证据提示部分腺体消融对局限性疾病男性是安全选择,但需更长期数据评估肿瘤学疗效与功能结局。
要点
- 纳入13项研究共543例,11项原发治疗、2项挽救治疗,中位随访6个月至10.6年。
- 治疗后勃起功能障碍0%至48%、尿失禁0%至50%,定义各研究不一。
- 共报告254例并发症,76例(14%)后续接受进一步肿瘤治疗。
核心结论
- 早期证据提示部分腺体消融是局限性疾病男性的安全治疗选择,但需更长期数据评估肿瘤学疗效与功能结局,并有助于确定最佳治疗候选者。
- 结局定义的标准化将有助于更好地比较不同研究及不同治疗方式。
研究设计与样本
- 遵循PRISMA指南的系统综述,使用MeSH词、自由文本检索并检查相关参考文献,检索MEDLINE与Embase自各数据库建库至2016年10月10日。
- 排除仅描述全腺体消融的研究、病例报告以及治疗后立即切除的系列。
- 共纳入13项研究,入组543例患者;其中11项研究在原发治疗背景、2项在挽救治疗背景进行。
- 中位随访范围为6个月至10.6年。
主要发现
- 治疗后勃起功能障碍发生率范围为0%至48%,尿失禁发生率范围为0%至50%,定义因研究而异。
- 总体共报告254例并发症。
- 研究间存在明显异质性,限制了功能与肿瘤学结局的合并分析。
- 共76例患者(14%)随后接受了进一步肿瘤治疗。
临床怎么用
- 作者认为早期证据提示部分腺体消融是局限性疾病男性的安全治疗选择。
- 作者指出需更长期数据评估肿瘤学疗效与功能结局,并有助于确定最佳治疗候选者。
局限性
- 研究间存在明显异质性,限制了功能与肿瘤学结局的合并分析。
- 需要更长期数据评估肿瘤学疗效与功能结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Advances in prostate imaging, biopsy and ablative technologies have been accompanied by growing enthusiasm for partial gland ablation, particularly using high-intensity focused ultrasound, to treat prostate cancer. Preserving noncancerous prostate tissue and minimizing damage to the neurovascular bundles and external urethral sphincter may improve functional outcomes. MATERIALS AND METHODS: A systematic review was performed following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines using a combination of MeSH® terms, free text search and examination of relevant bibliographies using MEDLINE® and Embase® from the inception of each database through October 10, 2016. We excluded studies describing exclusively whole gland ablation, case reports and series where treatment was followed by immediate resection. RESULTS: A total of 13 studies that enrolled 543 patients were included. Of the studies 11 were performed in the primary setting and 2 in the salvage setting. Median followup ranged from 6 months to 10.6 years. Rates of posttreatment erectile dysfunction and urinary incontinence ranged from 0% to 48% and 0% to 50%, respectively, with definitions varying by study. Overall there were 254 reported complications. Marked heterogeneity between studies limited the ability to pool results regarding functional and oncologic outcomes. A total of 76 patients (14%) subsequently received further oncologic treatment. CONCLUSIONS: Early evidence suggests that partial gland ablation is a safe treatment option for men with localized disease. Longer term data are needed to evaluate oncologic efficacy and functional outcomes, and will aid in identifying the optimal candidates for therapy. Standardization of outcomes definitions will allow for better comparison between studies and among treatment modalities.
引用
- Golan R, Bernstein AN, McClure TD, et al. Partial Gland Treatment of Prostate Cancer Using High-Intensity Focused Ultrasound in the Primary and Salvage Settings: A Systematic Review. J Urol. 2017. PMID: 28433640. doi:10.1016/j.juro.2017.03.137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。